annan naturvetenskaplig och teknisk forskning och utveckling
Company profile
Ticker
APRE
Exchange
Website
CEO
Christian S. Schade
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aprea Therapeutics AB • Aprea US, Inc. • ATR Pharmaceuticals LLC ...
APRE stock data
Latest filings (excl ownership)
8-K
IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented
10 Apr 24
S-3
Shelf registration
3 Apr 24
8-K
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
12 Mar 24
424B3
Prospectus supplement
9 Feb 24
8-K
Other Events
6 Feb 24
EFFECT
Notice of effectiveness
5 Feb 24
424B3
Prospectus supplement
5 Feb 24
8-K
Results of Operations and Financial Condition
2 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.39 mm | 25.39 mm | 25.39 mm | 25.39 mm | 25.39 mm | 25.39 mm |
Cash burn (monthly) | 777.12 k | 643.22 k | 1.17 mm | 1.20 mm | 748.28 k | 1.03 mm |
Cash used (since last report) | 5.19 mm | 4.30 mm | 7.84 mm | 8.04 mm | 5.00 mm | 6.90 mm |
Cash remaining | 20.20 mm | 21.10 mm | 17.55 mm | 17.35 mm | 20.40 mm | 18.49 mm |
Runway (months of cash) | 26.0 | 32.8 | 14.9 | 14.4 | 27.3 | 17.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 3.67 bn |
Total shares | 5.99 mm |
Total puts | 0.00 |
Total calls | 104.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
HealthCap VII | 2.37 mm | $1.59 mm |
KDev Investments AB | 1.78 mm | $8.76 mm |
5AM Ventures IV | 619.16 k | $4.55 mm |
AIGH Capital Management | 349.30 k | $1.46 bn |
Hirschman Orin | 345.00 k | $1.74 mm |
Sio Capital Management | 280.00 k | $1.17 bn |
Worth Venture Partners | 87.17 k | $365.24 mm |
Walleye Capital | 82.36 k | $345.07 mm |
Vanguard | 27.34 k | $113.92 mm |
Geode Capital Management | 17.47 k | $73.24 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Hamill John P. | Common Stock | Grant | Acquire A | No | No | 0 | 3,365 | 0.00 | 18,868 |
28 Mar 24 | Hamill John P. | Stock Options Common Stock | Grant | Acquire A | No | No | 6.69 | 13,460 | 90.05 k | 13,460 |
28 Mar 24 | Oren Gilad | Common Stock | Grant | Acquire A | No | No | 0 | 6,725 | 0.00 | 331,495 |
28 Mar 24 | Oren Gilad | Stock Options Common Stock | Grant | Acquire A | No | No | 6.69 | 26,900 | 179.96 k | 26,900 |
13 Mar 24 | Henneman John B Iii | Common Stock | Buy | Acquire P | No | No | 7.29 | 6,860 | 50.01 k | 8,139 |
13 Mar 24 | Henneman John B Iii | Tranche B Warrant Common Stock | Buy | Acquire P | No | No | 0 | 3,430 | 0.00 | 3,430 |
13 Mar 24 | Henneman John B Iii | Tranche A Warrant Common Stock | Buy | Acquire P | No | No | 0 | 3,430 | 0.00 | 3,430 |
13 Mar 24 | Oren Gilad | Common Stock | Buy | Acquire P | No | No | 7.29 | 2,000 | 14.58 k | 324,770 |
13 Mar 24 | Oren Gilad | Tranche B Warrant Common Stock | Buy | Acquire P | No | No | 0 | 1,000 | 0.00 | 1,000 |
13 Mar 24 | Oren Gilad | Tranche A Warrant Common Stock | Buy | Acquire P | No | No | 0 | 1,000 | 0.00 | 1,000 |
News
Aprea Therapeutics Announces Presentations On Its Next Generation WEE1 Inhibitor, APR-1051, And A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024
10 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Apr 24
Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11
27 Mar 24
HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target
26 Mar 24
Aprea Therapeutics: Q4 Earnings Insights
26 Mar 24
Press releases
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
10 Apr 24
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26 Mar 24
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
11 Mar 24
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
11 Mar 24
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
5 Mar 24